Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two agents, indocyanine green and triamcinolone acetonide, used primarily in ophthalmology. Indocyanine green is a water-soluble dye that fluoresces in the near-infrared spectrum and is commonly used for angiography to visualize choroidal vasculature and guide photodynamic therapy. Triamcinolone acetonide is a synthetic corticosteroid with anti-inflammatory properties, often administered intravitreally to reduce retinal edema and exudation. The combination has been studied as part of sequenced or combined therapies for retinal diseases such as retinal angiomatous proliferation (RAP), where triamcinolone reduces edema prior to indocyanine green-guided photodynamic therapy[1][2][4]. Both agents are also individually used intraoperatively for visualization during macular surgery[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indocyanine green + triamcinolone acetonide.